Malignant Neoplasms of Lip Oral Cavity and Pharynx Active Not Recruiting Phase 2 Trials for Utomilumab (DB15113)

IndicationStatusPhase
DBCOND0081505 (Malignant Neoplasms of Lip Oral Cavity and Pharynx)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03258008Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal CancerTreatment